Back
Lilly's Zepbound Combo Boosts Arthritis Efficacy by 64%
Back
Stock News
Themes
Lilly's Zepbound Combo Boosts Arthritis Efficacy by 64%
Lilly's Zepbound Combo Boosts Arthritis Efficacy by 64%
Edgen Stock
·
Jan 09 2026, 09:23
Share to
Share to
Copy link
LLY
+0.21%
source:
[1] Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight - Eli Lilly
Recommend
Celanese Q4 Earnings Plunge 54%, Missing Estimates
Feb 17 2026, 23:34
RB Global Beats Q4 Estimates With $1.11 EPS
Feb 17 2026, 23:33
Mercury General Crushes Q4 Forecasts With $3.66 EPS
Feb 17 2026, 23:32
Features
AI Copilot for Stock & Crypto
Price Prediction
Fundraise Tracker
Themes
Crypto Comparison
Home Page
Resources
Tutorial
Gitbook
Team
Aura Insights
Market
US Market
HK Market
Crypto Market
Terms of Use
Privacy Policy
Sitemap
© 2026 Finture Development Limited. All rights reserved
Edgen Stock·Jan 09 2026, 09:23Edgen Stock·Jan 09 2026, 09:23
Edgen Stock·Jan 09 2026, 09:23